Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$295,500.00
Nov 1, 2021
For-profit organization
Development of Novel Apelin Analog Drugs for Treatment of Cardiovascular Diseases
980844
PEARKO Therapeutics has been developing ApelinPlus (apelin analog) which can be a treatment for cardiovascular diseases. Currently, we are conducting preclinical testing of ApelinPlus, establishing required procedures, and preparing for regulatory filings with Health Canada, the Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
$140,000.00
Jan 1, 2020
For-profit organization
Preclinical Development of Apelin Analog and Completion of Regulatory Procedures
939480
PEARKO Therapeutics’s apelin analog will be synthesized by Bachem, a Good Manufacturing Practices (GMP)-certified producer of peptides for clinical use. We will use study findings to optimize intravenous and subcutaneous formulations of our biologic, and scale-up production. Over the same period, regulatory filings will be completed for Health Canada, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to augment the clinical trial process and international market entry. Completion of these steps will allow PEARKO Therapeutics to proceed through the final stages of preclinical development and complete the Investigational New Drug application, mandated by the FDA, in anticipation of Phase I clinical trials in 2022.